Results 81 to 90 of about 7,735 (212)

Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591 [PDF]

, 2021
Objectives: Rifampicin, a potent first-line TB drug of the rifamycin group, shows only little activity against the emerging pathogen Mycobacterium abscessus.
Roditscheff, Anna, Böttger, Erik C., Rominski, Anna, Selchow, Petra, Sander, Peter   +4 more
core  

Studies on the derivative of 3-Formyl Rifamycin SV [PDF]

, 1980
3-formyl rifamycin SV와 L-2-amino-I-butanol을 1 : 1의 몰 비로 20~25℃에서 다음과 같이 반응시켜서 흑자색의 결정을 얻었다. ◁그림 삽입▷(원문을 참조하세요) 이 화합물은 3-formyl rifamycin SV의 -CHO기와 L-2-amino-1-butanol의 -NH₂기 사이에서 Schiff's base가 된 것이며 그 λmax는 312nm, 555nm에 있었고 쉽게 가수분해되어 3 ...
李世允
core  

Production and purification of a bioactive substance against multi-drug resistant human pathogens from the marine-sponge-derived Salinispora sp.

Asian Pacific Journal of Tropical Biomedicine, 2014
Objective: To isolate, purify, characterize, elucidate structure and evaluate bioactive compounds from the sponge-derived Salinispora sp. FS-0034. Methods: The symbiotic actinomycete strain FS-0034 with an interesting bioactivity profile was isolated ...
Satyendra Singh, Pritesh Prasad, Ramesh Subramani, William Aalbersberg   +3 more
doaj   +1 more source

Whole genome sequence of the rifamycin B-producing strain Amycolatopsis mediterranei S699 [PDF]

, 2011
Amycolatopsis mediterranei S699 is an actinomycete that produces an important antibiotic, rifamycin B. Semisynthetic derivatives of rifamycin B are used for the treatment of tuberculosis, leprosy, and AIDS-related mycobacterial infections.
Tyagi, K. Akhilesh, Verma, Mansi, Anand, Shailly, Saxena, Anjali, Ravi, Vydianathan, Nigam, Aeshna, Kaur, Jaspreet, Khurana, Paramjit, Kumar, Mukesh, Kumari, Kirti, Khurana, P. Jitendra, Raghuvanshi, Saurabh, Lal, Rup   +12 more
core   +3 more sources

Continuous carbon source supply is essential for high rifamycin productivity of Amycolatopsis mediterranei in nitrate-stimulated fermentation revealed by a metabolomic study

Acta Biochimica et Biophysica Sinica
Amycolatopsis mediterranei U32 is an industrial strain capable of producing therapeutically useful rifamycin SV.
Yan Qi, Shao Zhihui, Yang Chen, Zhao Guoping   +3 more
doaj   +1 more source

Clinical and pharmacological hallmarks of rifapentine’s use in diabetes patients with active and latent tuberculosis: do we know enough?

Drug Design, Development and Therapy, 2017
Chunlan Zheng,1,* Xiufen Hu,2,* Li Zhao,1 Minhui Hu,1 Feng Gao3 1Department of Internal Medicine – Section 5, Wuhan Pulmonary Hospital (Wuhan Tuberculosis Control Institute), 2Department of Paediatrics, Tongji Hospital, 3Department of ...
Zheng C, Hu X, Zhao L, Hu M, Gao F
doaj  

Effect of topical rifamycin application on epidural fibrosis in rats [PDF]

, 2019
Objectives: This study aims to investigate the effects of topical rifamycin SV application on epidural fibrosis formation in a rat model. Materials and methods: Between March 2015 and April 2015, a total of 20 Wistar rats were equally and randomly ...
Tokmak, Mehmet, Er, Uygur, Tuncer, Cengiz, Türkoğlu, Mehmet Erhan, Dinç, Cem, Ocak, Pınar, Er, Uyur   +6 more
core   +1 more source

LC-MS-Based Metabolomics Study of Marine Bacterial Secondary Metabolite and Antibiotic Production in Salinispora arenicola

Marine Drugs, 2015
An LC-MS-based metabolomics approach was used to characterise the variation in secondary metabolite production due to changes in the salt content of the growth media as well as across different growth periods (incubation times). We used metabolomics as a
Utpal Bose, Amitha K. Hewavitharana, Yi Kai Ng, Paul Nicholas Shaw, John A. Fuerst, Mark P. Hodson   +5 more
doaj   +1 more source

Biosynthesis of Rifamycine [PDF]

Pathologia et Microbiologia, 2008
M, Liersch, J, Auden, J, Gruner, J, Nüesch   +3 more
openaire   +2 more sources

Exploring Rifamycin Inactivation from the Soil Microbiome [PDF]

, 2014
Our battle against pathogens has become a challenge due to the rise in antibiotic resistance and the dwindling number of new antibiotics entering the clinic.
Spanogiannopoulos, Peter
core